Healthcare technology Dutch giant Royal Philips will purchase Spectranetics, a Colorado-based company that employs vascular intervention to treat coronary and peripheral artery disease.
Philips announced it would pay $2.2 billion for the acquisition.
The board of directors of Spectranetics approved the transaction. It is expected to close in the third quarter of 2017 and expand and bolster Philips’ Image-Guided Therapy Business Group.
